Invalidity dossier
US 6054561
Antigen-binding sites of antibody molecules specific for cancer antigens
Current assignee: Novartis Vaccines and Diagnostics Inc
Added 9/23/2026, 8:45:45 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US 6,054,561 A
Title: "Antigen-binding sites of antibody molecules specific for cancer antigens"
Assignee/current assignee listed: Novartis Vaccines and Diagnostics Inc (original assignee Chiron Corp; inventor David B. Ring).
Key dates: Priority date 1984-02-08; application US08/483,749 filed 1995-06-07; granted/published 2000-04-25; anticipated expiration 2017-04-25; status "Expired – Lifetime." A priority claim from US06/690,750 (1985-01-11) and from US08/288,981 (1994-08-11) is noted.
Purpose: The invention concerns novel compositions derived from antigen-binding sites of immunoglobulin molecules specific for cancer antigens — molecules exhibiting the immunological binding properties of antibody antigen-binding sites, useful in specific binding assays, affinity purification, drug or toxin targeting, imaging, and genetic or immunological therapeutics for cancers. It provides polypeptides with structure and function substantially homologous to native antibody antigen-binding sites, the DNAs encoding them, expression cassettes comprising those DNAs, and methods of inducing their production.
Plain-language scope: The disclosure covers nucleic acid molecules encoding monomeric polypeptides containing amino acid residues homologous to complementarity determining regions (CDRs) from heavy (VH) or light (VL) domains of antibodies that bind specific human tumor antigens — the HMW mucins bound by 2G3 and 369F10, c-erbB-2 tumor antigen, approximately 42 kD and 55 kD glycoproteins, and the approximately 40, 60, 100 and 200 kD antigens bound by 113F1. CDR residues are displayed as projecting loops forming an antigen-binding surface, flanked by framework regions (FRs). Also described: CDR-switching to alter antigen-binding specificity, synthetic variable domains with murine CDR sets supported by human immunoglobulin FRs, and single-chain Fv (sFv) molecules. Classifications include C07K16/32 (antibodies against oncogene translation products) and C07K2317/622 (single-chain antibody).
Source: https://patents.google.com/patent/US6054561/en
What the excerpt does not establish: It does not provide the full claims, the complete specification or examples, exact sequences, or efficacy data. Litigation, ownership transfers, validity, and prior art are outside this summary and were not researched.
Generated 10/1/2026, 9:41:11 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 6054561. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.